Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Increased Occurrences Of Parasomnia Symptoms Experienced By Obstructive Sleep Apnea Patients
Patients suffering from obstructive sleep apnea (OSA) have an increased prevalence of parasomnia symptoms compared with the prevalence rates of individual parasomnias, according to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
generic viagra online
Watson Pharmaceuticals Receives A Complete Response Letter For Its 24-Week Formulation Of TRELSTAR(R) (triptorelin Pamoate) NDA From US FDA
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for TRELSTAR(R) 22.5 mg (triptorelin pamoate for injectable suspension), a 24-week formulation of TRELSTAR(R) for the palliative treatment of advanced prostate cancer. The TRELSTAR(R) NDA was prepared in cooperation with Debiopharm Group, a Swiss-based global biopharmaceutical group of companies.
News of the day
American Association For Homecare Supports Expanded Federal Efforts By DOJ And HHS To Combat Medicare Fraud
The American Association for Homecare supports expanded anti-fraud efforts announced today by the U.S. Department of Justice (DOJ) and the Department of Health and Human Services (HHS) designed to curb fraud and abuse in Medicare. The two agencies outlined plans for expanding anti-fraud strike forces to Houston and Detroit and creating a new Health Care Fraud Prevention and Enforcement Action Team.
Cardiovascular

Ductal Adenocarcinoma Of The Prostate: Clinical Features And Implications After Local Therapy

UroToday.com - An unspoken and perhaps forgotten enigma of cancer is its relative drug sensitivity. After all, when treated with cytotoxic agents, a tumor may regress while most normal tissues and organs are either left virtually intact or become eventually healed. Only because a tumor rarely gets into a complete remission, and keeps recurring despite treatment, do we consider cancer generally drug-resistant. Does this dichotomy of drug sensitivity versus resistance allude to a secret about cancer"s complex nature and mysterious origin? An important clinical implication of the stem-cell theory of cancer relates to the role of surgery to overcome drug resistance. Surgery is particularly efficacious for the removal of cancer stem cells that remain locally confined for a prolonged period of time. Whether surgery succeeds in the elimination of drug resistance and the eradication of cancer stem cells depends on the selection of appropriate patients with the right tumor types. Importantly, the theory of a stem-cell origin of cancers provides us with the rationale and offers us some clues of who may be the ideal candidates and what may the right tumors for primary surgery, for metastatectomy, and for neoadjuvant or adjuvant strategies. Indeed, this is yet another facet to the drug-resistant story. So far, we have focused on the more obvious aspects of drug resistance: dormancy, multi-drug resistance, DNA repair, and apoptosis. Often enough, we have neglected to mention another key aspect of drug resistance: the indolent but intractable differentiated tumor, which behaves just like a normal tissue that is left virtually intact or becomes eventually healed in the face of noxious cytotoxic therapies. Like their respective cancer stem cells, certain differentiated cancer cells are also inherently dormant and multi-drug-resistant; they are more than adept in undergoing DNA repair and avoiding apoptosis. Like a malignant "teratoma," such tumors are invulnerable to the effects of various therapies and need to be extirpated by surgery. Written by Shi-Ming Tu, MD, et al. as part of Beyond the Abstract on UroToday.com. UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009